Swissmedic approves Novartis

3 November 2008

Swiss drug major Novartis' Rasilez HCT (aliskiren and hydrochlorothiazide), a single-pill combination of two high blood pressure medicines - the first-in-class direct renin inhibitor Rasilez (aliskiren) and the diuretic hydrochlorothiazide - has been approved by Swissmedic as a new treatment for high blood pressure. The first new type of blood pressure medicine in over a decade, Rasilez, known as Tekturna in the USA, provides effective blood pressure lowering that lasts beyond 24 hours, Novartis noted, adding that HCT is one of the most commonly-used diuretics in the treatment of hypertension, which affects nearly one in four adults worldwide. The Basel-headquartered firm said it expects Europe-wide approval early next year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight